NEWS
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech Inc. (Nasdaq: NKGN) announced upcoming poster presentations at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain from October 29 – November 1, 2024. The presentations will cover:
1. A final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in Alzheimer's disease subjects.
2. Further biomarker analysis and implications for use in prevention of Alzheimer's disease using non-genetically modified natural killer cells (SNK01) with enhanced activity.
The posters will be presented during Poster Session 1 on October 29-30, 2024. Full abstracts will be included in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD).
1. A final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in Alzheimer's disease subjects.
2. Further biomarker analysis and implications for use in prevention of Alzheimer's disease using non-genetically modified natural killer cells (SNK01) with enhanced activity.
The posters will be presented during Poster Session 1 on October 29-30, 2024. Full abstracts will be included in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD).
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
